211 related articles for article (PubMed ID: 21198707)
21. Review article: current antiviral therapy of chronic hepatitis B.
Ayoub WS; Keeffe EB
Aliment Pharmacol Ther; 2008 Jul; 28(2):167-77. PubMed ID: 18466358
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Murata K; Tsukuda S; Suizu F; Kimura A; Sugiyama M; Watashi K; Noguchi M; Mizokami M
Hepatology; 2020 May; 71(5):1533-1545. PubMed ID: 31529730
[TBL] [Abstract][Full Text] [Related]
23. New therapeutic perspectives in HBV: when to stop NAs.
Pérez-Cameo C; Pons M; Esteban R
Liver Int; 2014 Feb; 34 Suppl 1():146-53. PubMed ID: 24373092
[TBL] [Abstract][Full Text] [Related]
24. [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
Juszczyk J; Boroń-Kaczmarska A; Cianciara J; Flisiak R; Gładysz A; Halota W; Kryczka W; Malkowski P; Pawlowska M; Simon K;
Pol Merkur Lekarski; 2010 Aug; 29(170):103-6. PubMed ID: 20842822
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hepatitis B: Is there still a role for interferon?
Viganò M; Grossi G; Loglio A; Lampertico P
Liver Int; 2018 Feb; 38 Suppl 1():79-83. PubMed ID: 29427498
[TBL] [Abstract][Full Text] [Related]
26. Medical therapy of patients affected by HBeAg-negative chronic hepatitis B.
Marcellin P; Boyer N; Asselah T
Minerva Gastroenterol Dietol; 2006 Mar; 52(1):23-38. PubMed ID: 16554704
[TBL] [Abstract][Full Text] [Related]
27. [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Tornai I
Orv Hetil; 2011 May; 152(22):869-74. PubMed ID: 21565754
[TBL] [Abstract][Full Text] [Related]
28. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
Matsumoto A; Nishiguchi S; Enomoto H; Kang JH; Tanaka Y; Shinkai N; Kurosaki M; Enomoto M; Kanda T; Yokosuka O; Yatsuhashi H; Nagaoka S; Okuse C; Kagawa T; Mine T; Takaguchi K; Saito S; Hino K; Ikeda F; Sakisaka S; Morihara D; Miyase S; Tsuge M; Chayama K; Hiramatsu N; Suzuki Y; Murata K; Tanaka E
J Gastroenterol; 2018 Feb; 53(2):247-257. PubMed ID: 28634723
[TBL] [Abstract][Full Text] [Related]
29. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
[TBL] [Abstract][Full Text] [Related]
30. Drugs in development for hepatitis B.
Buti M; Esteban R
Drugs; 2005; 65(11):1451-60. PubMed ID: 16033287
[TBL] [Abstract][Full Text] [Related]
31. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
32. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Pipili C; Cholongitas E; Papatheodoridis G
Aliment Pharmacol Ther; 2014 Jan; 39(1):35-46. PubMed ID: 24299322
[TBL] [Abstract][Full Text] [Related]
33. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
[TBL] [Abstract][Full Text] [Related]
35. Emerging pipeline drugs for hepatitis B infection.
Cox N; Tillmann H
Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
[TBL] [Abstract][Full Text] [Related]
36. Current practice of chronic hepatitis B treatment in Southern Italy.
Stroffolini T; Spadaro A; Di Marco V; Scifo G; Russello M; Montalto G; Bertino G; Surace L; Caroleo B; Foti G; Portelli V; Madonia S; Sapienza M; Cosco L; Frugiuele P; Galdieri A; Brandolino N; Siciliano R; Bruno S; Almasio PL;
Eur J Intern Med; 2012 Jul; 23(5):e124-7. PubMed ID: 22726382
[TBL] [Abstract][Full Text] [Related]
37. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
Tang CM; Yau TO; Yu J
World J Gastroenterol; 2014 May; 20(20):6262-78. PubMed ID: 24876747
[TBL] [Abstract][Full Text] [Related]
38. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
[TBL] [Abstract][Full Text] [Related]
39. [Chronic hepatitis B: current therapy].
Buffet C
Bull Acad Natl Med; 2008 Nov; 192(8):1625-37; discussion 1638-9. PubMed ID: 19445377
[TBL] [Abstract][Full Text] [Related]
40. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Petersen J; Buti M
Expert Rev Gastroenterol Hepatol; 2012 Dec; 6(6):683-93; quiz 694. PubMed ID: 23237254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
